- Previous Close
9.78 - Open
9.30 - Bid 9.34 x 800
- Ask 9.66 x 800
- Day's Range
9.21 - 9.72 - 52 Week Range
9.21 - 19.18 - Volume
3,371,526 - Avg. Volume
1,422,290 - Market Cap (intraday)
1.538B - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.22
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
www.certara.com1,487
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CERT
View MorePerformance Overview: CERT
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERT
View MoreValuation Measures
Market Cap
1.54B
Enterprise Value
1.67B
Trailing P/E
--
Forward P/E
21.01
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.98
Price/Book (mrq)
1.45
Enterprise Value/Revenue
4.34
Enterprise Value/EBITDA
23.08
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.13%
Return on Assets (ttm)
0.75%
Return on Equity (ttm)
-1.15%
Revenue (ttm)
385.15M
Net Income Avi to Common (ttm)
-12.05M
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
181.4M
Total Debt/Equity (mrq)
29.46%
Levered Free Cash Flow (ttm)
67.68M